Abstract:Background Mortality and other clinical outcomes of culture-negative and culture-positive among patients with fungal sepsis have not been documented, and whether antifungal therapy prior to fungal culture reports is related to decreased mortality among patients remains largely controversial. This study aimed to determine the mortality and other clinical outcomes of patients with positive yeast cultures and further investigate the effects of initial empiric antifungal therapy. Methods A retrospective study was conducted among septic patients using the Medical Information Mart for Intensive Care (MIMIC)-IV database. Patients with sepsis were divided into two groups based on first fungal culture status during intensive care unit (ICU) stay, and initial empirical antifungal therapy was prescribed based on physician’s experience prior to fungal culture reports within 48 h. The primary outcome was in-hospital all-cause mortality. The secondary outcomes were 30-day all-cause mortality, 60-day all-cause mortality, length of ICU stay and length of hospital stay. Multivariate logistic regression, propensity score matching (PSM), subgroup analyses and survival curve analyses were performed. Results This study included 18,496 sepsis patients, of whom 3,477 (18.8%) had positive yeast cultures. Patients with positive yeast cultures had higher in-hospital all-cause mortality, 60-day all-cause mortality, and longer lengths of ICU stay and hospital stay than those with negative yeast cultures after PSM (all p < 0.01). Multivariate logistic regression analysis revealed that positive yeast culture was a risk factor for in-hospital mortality in the extended model. Subgroup analyses showed that the results were robust among the respiratory infection, urinary tract infection, gram-positive bacterial infection and bacteria-free culture subgroups. Interestingly, empiric antifungal therapy was not associated with lower in-hospital mortality among patients with positive yeast cultures, mainly manifested in stratification analysis, which showed that antifungal treatment did not improve outcomes in the bloodstream infection (odds ratio, OR 2.12, 95% CI : 1.16–3.91, p = 0.015) or urinary tract infection groups ( OR 3.24, 95% CI : 1.48–7.11, p = 0.003). Conclusion Culture positivity for yeast among sepsis patients was associated with worse clinical outcomes, and empiric antifungal therapy did not lower in-hospital all-cause mortality in the bloodstream infection or urinary tract infection groups in the ICU.

Impact of Initial Empirical Antifungal Agents on the Outcome of Critically Ill Patients with Invasive Candidiasis: Analysis of the China-SCAN Study

Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Invasive Candidiasis in Intensive Care Units in China: a Multicentre Prospective Observational Study

Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study.

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

Empiric Treatment Against Invasive Fungal Diseases in Febrile Neutropenic Patients: a Systematic Review and Network Meta-Analysis

Does High-Dose Cytarabine Cause More Fungal Infection in Patients with Acute Myeloid Leukemia Undergoing Consolidation Therapy A Multicenter, Prospective, Observational Study in China

A Ten-Year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital

Impact of early empirical antifungal therapy on prognosis of sepsis patients with positive yeast culture: A retrospective study from the MIMIC-IV database

Appropriate Source Control and Antifungal Therapy Are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis

Epidemiology, Clinical Characteristics, and Risk Factors for Mortality of Early- and Late-Onset Invasive Candidiasis in Intensive Care Units in China.

Invasive Candidiasis in Intensive Care Units in China: Risk Factors and Prognoses of Candida Albicans and Non-Albicans Candida Infections

ICU Patients’ Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data

A Ten-year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital in Beijing.

Antifungal susceptibility, molecular epidemiology, and clinical risk factors of Candida glabrata in intensive care unit in a Chinese Tertiary Hospital

Clinical Features and Prognostic Risk Factors of Candidemia in Non-Intensive Care Unit Wards

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

Impact of Invasive Fungal Infection on Outcomes of Severe Sepsis: a Multicenter Matched Cohort Study in Critically Ill Surgical Patients

Clinical efficacy and safety of antifungal drugs for the treatment of Candida parapsilosis infections: a systematic review and network meta-analysis